Renaissance Capital logo

Vascular Biogenics Priced, Nasdaq: VBLT

Developing gene therapies for cancer and small molecules for inflammation.

Industry: Health Care

First Day Return: -2.5%

Developing gene therapies for cancer and small molecules for inflammation.

Vascular Biogenics (VBLT) Performance

Created with Highcharts 10.3.2Chart context menuVBLT vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index